
Cantargia Q1 2025 - Approaching Crucial TRIFOUR Readout

Q1 was an active quarter for Cantargia. Among other things, positive multiple ascending dose results for CAN10 were presented, pre-clinical data from a new IL1-RAP ADC were presented, and TRIFOUR was fully recruited, with a first ORR readout expected by mid-2025.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Cantargia Q1 2025 - Approaching Crucial TRIFOUR Readout